Center for Disease Analysis. Estimates of the coverage of diagnosis and treatment for HBV and HCV infection, by WHO region and income group, 2015. April 2017. Summary In May 2016, the World Health Assembly endorsed the Global Health Sector Strategy (GHSS) on viral hepatitis 2016–2021. The GHSS calls for the elimination of viral hepatitis as a […]
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on a National Strategy for the Elimination of Hepatitis B and C. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. Strom BL, Buckley GJ, editors. Washington (DC): National Academies […]
European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017 May;2(5):325-336. doi: 10.1016/S2468-1253(17)30045-6. Epub 2017 Mar 15. PMID: 28397696. Summary Collaborators European Union HCV Collaborators: Homie Razavi, Sarah Robbins, Stefan Zeuzem, Francesco Negro, Maria Buti, Ann-Sofi Duberg, Françoise Roudot-Thoraval, Antonio […]
Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017 Mar 2;3:17006. doi: 10.1038/nrdp.2017.6. PMID: 28252637. Summary Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage, which might result in liver cirrhosis and hepatocellular carcinoma. Globally, between […]
Buti M, Calleja JL, García-Samaniego J, Serra MÁ, Crespo J, Romero M, Simón MÁ, Turnes J, Blasco AJ, Lázaro P, Robbins S, Razavi H; en representación del Grupo para el Estudio y Modelización Epidemiológica de la Hepatitis C en España (GEMEHCE). Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the […]
Hajarizadeh B, Grebely J, McManus H, Estes C, Razavi H, Gray RT, Alavi M, Amin J, McGregor S, Sievert W, Thompson A, Dore GJ. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. J Gastroenterol Hepatol. 2017 Jan;32(1):229-236. doi: 10.1111/jgh.13453. PMID: 27197716. Summary Background and aim Interferon-free direct-acting antiviral […]
Hepatitis B and C in the Spotlight. A public health response in the Americas, 2016. Washington, D.C. : PAHO; 2016.
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16. PMID: 28404132. Summary Collaborators Polaris Observatory HCV Collaborators: Sarah Blach, Stefan Zeuzem, Michael Manns, Ibrahim Altraif, Ann-Sofi Duberg, David H Muljono, Imam Waked, Seyed M Alavian, Mei-Hsuan Lee, Francesco Negro, Faisal Abaalkhail, Ahmed Abdou, Maheeba Abdulla, Antoine Abou Rached, Inka […]
Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts […]
Robaeys G, Bielen R, Azar DG, Razavi H, Nevens F. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol. 2016 Dec;65(6):1094-1103. doi: 10.1016/j.jhep.2016.07.042. Epub 2016 Aug 9. PMID: 27520879. Summary Hepatitis C viral infection after injection drug use is very prevalent. The most important genotype causing HCV infection in […]